Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan–furazolidone triple therapy vs bismuth-based quadruple therapy for H. pylori eradication
ChiCTR2300073141Phase 4Recruiting
- Sponsor
- Qingyuan People's Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Qingyuan People's Hospital. Primary endpoint: eradication rate of Helicobacter pylori infection. Started Nov 2022; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300073141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073141.